|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
125,280,000 |
Market
Cap: |
5.31(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.16 - $47.08 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 20.8 |
Insider 6 Months : 24.2 |
Insider 3/6 Months : 45.4 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Corbus Pharmaceuticals Holdings is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Co.'s pipeline includes anti-integrin monoclonal antibodies that block activation of Transforming growth factor B (TGFB) and small molecules that activate or inhibit the endocannabinoid system. Co.'s pipeline includes: anti-integrin monoclonal antibodies for the treatment of cancer and fibrosis that inhibit the activation of TGFB; cannabinoid receptor type 1 inverse agonists designed to treat obesity and related metabolic diseases; and lenabasum, a synthetic, oral molecule that activates cannabinoid receptor type 2.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
550,000 |
1,582,632 |
1,582,632 |
1,633,932 |
Total Buy Value |
$23,327,560 |
$46,689,501 |
$46,689,501 |
$46,703,200 |
Total People Bought |
1 |
2 |
2 |
5 |
Total Buy Transactions |
2 |
4 |
4 |
9 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tepper Mark |
President and CSO |
|
2018-11-14 |
4 |
OE |
$1.00 |
$10,000 |
D/D |
10,000 |
2,110,400 |
|
- |
|
Hochman David P |
Director |
|
2018-05-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
220,000 |
110,000 |
|
- |
|
Hochman David P |
Director |
|
2018-05-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
220,000 |
0 |
|
- |
|
White Barbara |
Chief Medical Officer |
|
2018-05-15 |
4 |
B |
$5.87 |
$15,174 |
D/D |
2,586 |
179,521 |
2.74 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2018-05-15 |
4 |
B |
$5.85 |
$10,091 |
D/D |
1,725 |
61,660 |
2.81 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2018-05-15 |
4 |
B |
$5.77 |
$23,080 |
D/D |
4,000 |
348,010 |
2.74 |
- |
|
Hochman David P |
Director |
|
2018-05-14 |
4 |
B |
$5.48 |
$27,375 |
I/I |
5,000 |
5,000 |
2.1 |
- |
|
Hochman David P |
Director |
|
2018-03-14 |
4 |
B |
$6.67 |
$33,325 |
I/I |
5,000 |
225,000 |
2.1 |
- |
|
White Barbara |
Chief Medical Officer |
|
2018-03-14 |
4 |
B |
$6.89 |
$19,878 |
D/D |
2,885 |
176,935 |
2.74 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2018-03-14 |
4 |
B |
$6.89 |
$7,987 |
D/D |
1,160 |
59,935 |
2.81 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2018-03-14 |
4 |
B |
$6.60 |
$20,460 |
D/D |
3,100 |
344,010 |
2.74 |
- |
|
Panayiotopoulos Paris |
Director |
|
2017-11-16 |
4 |
B |
$7.03 |
$100,392 |
D/D |
14,285 |
14,285 |
2.39 |
- |
|
Hochman David P |
Director |
|
2017-11-15 |
4 |
B |
$6.55 |
$32,750 |
I/I |
5,000 |
220,000 |
2.1 |
- |
|
Hochman David P |
Director |
|
2017-11-13 |
4/A |
B |
$6.90 |
$34,500 |
I/I |
5,000 |
215,000 |
2.1 |
- |
|
Hochman David P |
Director |
|
2017-11-13 |
4 |
A |
$6.90 |
$34,500 |
I/I |
5,000 |
215,000 |
|
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2017-11-10 |
4 |
B |
$7.17 |
$7,169 |
D/D |
1,000 |
58,775 |
2.81 |
- |
|
Hochman David P |
Director |
|
2017-11-10 |
4 |
B |
$7.08 |
$70,800 |
D/D |
10,000 |
459,500 |
2.39 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2017-11-10 |
4 |
B |
$7.04 |
$10,560 |
D/D |
1,500 |
340,910 |
2.74 |
- |
|
White Barbara |
Chief Medical Officer |
|
2017-11-10 |
4 |
B |
$7.00 |
$19,852 |
D/D |
2,836 |
174,050 |
2.74 |
- |
|
White Barbara |
Chief Medical Officer |
|
2017-08-11 |
4 |
B |
$6.05 |
$14,998 |
D/D |
2,479 |
171,214 |
2.74 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2017-08-11 |
4 |
B |
$6.00 |
$10,170 |
D/D |
1,695 |
57,775 |
2.81 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2017-08-11 |
4 |
B |
$5.91 |
$14,775 |
D/D |
2,500 |
339,410 |
2.74 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2017-05-11 |
4 |
B |
$6.14 |
$20,262 |
D/D |
3,300 |
336,910 |
2.74 |
- |
|
Holmer Alan F |
Director |
|
2017-05-11 |
4 |
B |
$6.23 |
$3,115 |
D/D |
500 |
22,500 |
2.31 |
- |
|
Hochman David P |
Director |
|
2017-05-11 |
4 |
B |
$6.18 |
$21,012 |
D/D |
3,400 |
459,500 |
2.39 |
- |
|
176 Records found
|
|
Page 3 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|